Delta-Fly Pharma Submits Phase I/II Protocol for DFP-10917 with VTX in VTX-Treated AML Patients

Delta-Fly Pharma, Inc., a pharmaceutical company based in Tokushima, Japan, has announced significant progress in their drug development pipeline. The company has recently completed the submission of a Phase I/II clinical trial protocol for a combination therapy involving their drug DFP-10917 and Venetoclax (VTX), specifically for acute myeloid leukemia (AML) patients who have previously received VTX treatment. This submission was made to the U.S. Food and Drug Administration (FDA) on March 8, 2024, and the study is set to commence at Wake Forest and other participating hospitals upon receiving FDA approval.
Additionally, Delta-Fly Pharma is conducting an interim analysis of a Phase III clinical trial for DFP-10917 in patients with recurrent or refractory AML across multiple centers in the United States. This analysis is crucial as it may reveal patients with extended survival times, which could impact the overall survival (OS) analysis of the study.
The company has also received patents for a combination treatment using DFP-14927 with VTX for AML in Japan, the United States, and Taiwan, further solidifying their innovative approach to cancer treatment. Delta-Fly Pharma encourages those interested in their work to reach out for more information.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!